Can someone help me with this?

Problem 16-5 Amy Dyken, controller at Fitzgerald Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Fitzgerald's financial statements. Below is selected financial information for the fiscal year ended June 30, 2014 FITZGERALD PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2014 Long-term debt Notes payable, 1096 7% convertible bonds payable 10% bonds payable $1,172,000 5,165,000 6,042,000 $12,379,000 Total long-term debt Shareholders' equity authorized, 25,825 shares issued and outstanding authorized, 1,003,100 shares issued and outstanding 103,300 shares Preferred stock, 6% cumulative, $53 par value, Common stock, $1 par, 10,031,000 shares Additional paid-in capital $1,368,725 1,003,100 4,001,900 6,004,000 $12,377,725 Retained earnings Total shareholders' equity The following transactions have also occurred at Fitzgerald 1. Options were granted on July 1, 2013, to purchase 210,000 shares at $15 per share. Although no options were exercised during fiscal year 2014, the average price per common share during fiscal year 2014 was $25 per share 2. Each bond was issued at face value. The 7% convertible bonds will convert into common stock at 53 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2013 3. The preferred stock was issued in 2013 4. There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2014 5. The 1,003,100 shares of common stock were outstanding for the entire 2014 fiscal year 6. Net income for fiscal year 2014 was $1,506,000, and the average income tax rate is 40% For the fiscal year ended June 30, 2014, calculate the following for Fitzgerald Pharmaceutical Industries. (Round answers to 2 decimal places, e.g $2.45.) (a) Basic earnings per share Basic earnings per share (b) Diluted earnings per share Diluted earnings per share